Longeveron (Longeveron) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Longeveron Dividend Payout Ratio?

Longeveron's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Longeveron's Dividend Payout Ratio or its related term are showing as below:

LGVN's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.455
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-14), the Dividend Yield % of Longeveron is 0.00%.

Longeveron's Dividends per Share for the months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Longeveron Dividend Payout Ratio Historical Data

The historical data trend for Longeveron's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron Dividend Payout Ratio Chart

Longeveron Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Longeveron Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Longeveron's Dividend Payout Ratio

For the Biotechnology subindustry, Longeveron's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longeveron's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Longeveron's Dividend Payout Ratio falls into.

Longeveron Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Longeveron's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-10.186
	=	N/A

Longeveron's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-2.487
	=	N/A

Longeveron (NAS:LGVN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Longeveron Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Longeveron's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Longeveron (Longeveron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136

Website

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.

Executives

Cathy Ross	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer	director
Lisa Locklear	officer: Chief Financial Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova	officer: Chief Medical Officer	1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo	officer: CFO and Treasurer	1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed	officer: Chief Executive Officer	SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare	director, officer: Chief Scientific Officer	C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min	officer: Chief Medical Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green	officer: CEO	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr	officer: General Counsel, Secretary	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer	director, 10 percent owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136